CLINICAL TRIALS PROFILE FOR MALARONE PEDIATRIC
✉ Email this page to a colleague
▶ Start for $100
Remove trial restrictions
All Clinical Trials for Malarone Pediatric
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00298610 ↗ | Safety and Efficacy Study of IV Artesunate to Treat Malaria | Completed | Military Infectious Diseases Research Program (MIDRP) | Phase 2 | 2006-03-01 | The purpose of this study is to determine how GMP IV Artesunate is metabolized and cleared by individuals with uncomplicated malaria infection and to determine how fast it eliminates malaria infection from the body. |
| NCT00298610 ↗ | Safety and Efficacy Study of IV Artesunate to Treat Malaria | Completed | U.S. Army Medical Research and Development Command | Phase 2 | 2006-03-01 | The purpose of this study is to determine how GMP IV Artesunate is metabolized and cleared by individuals with uncomplicated malaria infection and to determine how fast it eliminates malaria infection from the body. |
| NCT00298610 ↗ | Safety and Efficacy Study of IV Artesunate to Treat Malaria | Completed | U.S. Army Office of the Surgeon General | Phase 2 | 2006-03-01 | The purpose of this study is to determine how GMP IV Artesunate is metabolized and cleared by individuals with uncomplicated malaria infection and to determine how fast it eliminates malaria infection from the body. |
| NCT00421473 ↗ | Drug Interaction Study Between Atovaquone and Antiretroviral Agents in HIV-1 Infected Patients | Completed | Radboud University | Phase 4 | 2007-03-01 | Malarone® (atovaquone/proguanil) is frequently used in malaria prophylaxis. Unfortunately, there are indications that certain anti-HIV agents may decrease atovaquone plasma levels by induction of atovaquone metabolism. For travelling HIV patients, the clinical consequences of these possible drug drug interactions are serious, since a diminished exposure to the anti-malarial drug will result in suboptimal prophylaxis of malaria and potential development of drug resistant strains of Plasmodium falciparum. The purpose of this study is to find out if HIV patients using HAART regimes with either lopinavir/ritonavir, atazanavir/ritonavir or efavirenz have lower atovaquone plasma levels than healthy volunteers after a single dose of atovaquone/proguanil. |
| NCT00444106 ↗ | Evaluation of Potential Effect of Artemether - Lumefantrine and Malaria Drugs on Auditory Function | Completed | Novartis | Phase 4 | 2007-05-01 | To evaluate the potential effects of artemether- lumefantrine on the auditory function |
| NCT00984256 ↗ | Weekly Dosing of Malarone ® for Prevention of Malaria | Completed | U.S. Army Medical Research and Development Command | Phase 2 | 2009-09-01 | The purpose of this study is to determine whether Malarone ®, which is a drug approved to prevent malaria when taken daily, will still effectively prevent malaria if taken weekly. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Malarone Pediatric
Condition Name
Clinical Trial Locations for Malarone Pediatric
Trials by Country
Clinical Trial Progress for Malarone Pediatric
Clinical Trial Phase
Clinical Trial Sponsors for Malarone Pediatric
Sponsor Name
